New Products

Human CT83 (HLA-A*01:01) Protein (MHC-HM426)

Human CT83 (HLA-A*01:01) Tetramer Protein (MHC-HM426T)

Gene editing technology has undergone several generations of innovations, from the original ZFNs (zinc-finger nucleases) technology, TALENs (transcription activator-like effector nucleases) technology to CRISPR-Cas technology, to BE (base editing) technology and PE (prime editing) technology, etc., It has greatly improved the ability of humans to precisely modify the genome of eukaryotic cells, and provided the possibility of treating otherwise incurable diseases.

Due to the convenience of the design and operation, the CRISPR-Cas system has become the most widely used gene editing technology at present. The nucleases involved in this technology include Cas9, Cas9n, Cas12a, etc. Cas9 cuts DNA at 3bp upstream of the PAM sequence while Cas12a cuts at 18-23bp downstream of the PAM sequence.

GMP-Grade CRISPR Cas9

KACTUS offers GMP-grade Cas9 nuclease. Our Cas9 nuclease has been successfully submitted to the U.S. FDA Drug Master Files (DMF #036578). If you use KACTUS Cas9 nuclease for your gene therapy projects, you can directly quote our DMF number in the regulatory documentation for new drug registrations, to speed up your drug review filing.

Cell Based Editing Assay 

Figure 1. Cas9 is electrotransfected into 293T cell line in the form of RNP to knock out the target gene. Results show KACTUS Cas9 has the same knockout efficiency as leading competitors.	Figure 2. Cas9 cuts substrate DNA standard via in vitro cutting experiment. Results show the cleavage activity of KACTUS Cas9 is equivalent to that of leading competitors.

In Vitro Cleavage Activity

Highly Active Cas12a Nuclease

CRISPR-Cas12a (also known as Cpf1) is a RNA-guided endonuclease enzyme that belongs to the CRISPR-Cas gene editing system. It is a powerful tool for genome editing, as it has the ability to cleave double-stranded DNA at specific sites determined by a guide RNA molecule. Unlike the commonly used CRISPR-Cas9 system, Cas12a has unique features, including its smaller size, ability to recognize a different DNA target sequence, and ability to generate DNA overhangs. These characteristics make Cas12a a promising tool for genetic engineering, gene therapy, and diagnostic applications. Additionally, recent studies have shown that Cas12a can be used for specific detection of nucleic acids in a variety of samples, making it an attractive tool for molecular diagnostics.

	Figure 1. Cas9 is electrotransfected into 293T cell line in the form of RNP to knock out the target gene. Results show KACTUS Cas9 has the same knockout efficiency as leading competitors.
	Figure 2. Cas9 cuts substrate DNA standard via in vitro cutting experiment. Results show the cleavage activity of KACTUS Cas9 is equivalent to that of leading competitors.